| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
We report here that L13 is activated in human gastrointestinal cancers. By using qRT-PCR, we analyzed expression of L13 in freshly resected cancer tissue of the stomach, colorectum, and liver. Upregulation of L13 mRNA expression was observed in 10 (28%) of 36 stomach, 19 (41%) of 46 colorectal, and 5 (20%) of 25 liver cancer tissue samples compared to adjacent normal tissue samples. We also found that increased expression of the L13 gene was correlated with clinical staging in stomach cancers. Importantly, we discovered that L13 expression was inversely related to p53 mutational status in primary gastric cancer, and siRNA-mediated L13 suppression resulted in robust induction of p53 protein. These findings suggest that L13 plays an essential role in the progression of some gastrointestinal malignancies by numbing the p53 pathway, thus allowing tumorigenic growth in the presence of wild-type p53.
|
